Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Core Insights - Senti Biosciences, Inc. is advancing its clinical trials for SENTI-202, targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][4] - The company has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of SENTI-202 [3] - Senti Bio is also preparing to initiate a pilot trial for SENTI-301A in hepatocellular carcinoma (HCC) in China through a partnership with Celest Therapeutics [2][5] Corporate and Pipeline Highlights - The Phase 1 clinical trial for SENTI-202 has commenced, focusing on patients with relapsed/refractory AML in the U.S. and Australia, with initial efficacy data expected by the end of 2024 [4] - The company is developing SENTI-301A for solid tumors in China, with the first patient expected to be dosed in Q4 2024 [5] - A reverse stock split of 1-for-10 was executed in July 2024 to comply with Nasdaq's minimum bid price requirement [6] Financial Results - As of June 30, 2024, Senti Bio reported cash and cash equivalents of $15.9 million, with additional receivables of $18.9 million anticipated from the GeneFab transaction [7] - Research and development expenses increased to $9.2 million for Q2 2024, up from $6.9 million in Q2 2023, primarily due to manufacturing costs [7] - General and administrative expenses decreased to $4.2 million in Q2 2024 from $9.2 million in Q2 2023, attributed to a reduction in headcount [7] Upcoming Events - Senti Bio plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and Chardan's 8th Annual Genetic Medicines Conference from September 30 to October 1, 2024 [8]